Oncology Times - OncTimes Talk cover art

All Episodes

Oncology Times - OncTimes Talk — 198 episodes

#
Title
1

Program 4, Day 4, Monday Dec 8

2

Program 3, Monday Dec 7

3

Program 2, Sunday Dec. 6

4

Program 1, First Day, Dec. 5

5

ASH Annual Meeting

6

NCRI Conference, ASCO Annual Meeting, and Perspectives in Lung Cancer European Congress

7

KRAS-Driven Selection of Molecular Therapy for Metastatic Colorectal Cancer: Choosing Between Bevacizumab, Cetuximab, Panitumomab, or a Combination

8

CML: Hagop Kantarjian on Treating Patients with the T315I Mutation

9

Oropharyngeal Cancer: Better Outlook with HPV-Directed Therapies

10

Breast Cancer: St. Gallen Meeting Endorses Multi-Gene Assays for Refining Chemo Decision

11

The Smartest Oncologist in the World? – Well, at least in the US!

12

Cancer-Related Fatigue

13

Bilateral Prophylactic Mastectomy for DCIS

14

10th European Congress on Perspectives in Lung Cancer, Brussels

15

More from the ASH Annual Meeting!

16

OT Clinical Advisory Editor for Hematology/Oncology Mikkael Sekeres, MD, MS

17

OT Clinical Advisory Editor for Oncology Ramaswamy Govindan, MD

18

Treatment Recommendations for High- & Low-Risk Early Breast Cancer: New Data from EBCC 7, the European Breast Cancer Conference

19

Pregnancy & Breast Cancer: New Updates from EBCC 7, the European Breast Cancer Conference

20

Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!

21

Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome

22

Research Policy Expert: Overhaul Cancer Research Priorities Globally Now!

23

Swedish Registry Study Shows Hormone Therapy for Prostate Cancer Increased All Cardiovascular Mortality

24

The Disappointment of the NSABP C-08 Trial

25

Advanced Biliary Cancer Controlled with Cetuximab Added to GEMOX

26

Metastatic Colorectal Cancer: Capecitabine Equivalent to 5-FU in Irinotecan/Bevacizumab Combos

27

Stage IV Pancreatic Islet Cell Tumors: Sunitinib Doubles Progression-Free Survival in Phase III Study

28

The Role of Patient Education in Survivorship Care

29

How CancerLinQ Will Change Patient Care

30

How Drug Shortages Affect Oncology

31

The Thinking Behind ASCO’s Top Five List

32

The Value of In-Person Meetings

33

Oncology Practices Expect Big Change

34

Cancer’s Existential Impact on Survivors

35

How Should Physicians Be Paid?

36

Integrating Palliative & Standard Care

37

The Importance of “Competitive Mortality” in Oncology Care

38

Final Rule for Medicare ACOs

39

Will CMS Cast Its Eye Toward Oncology?

40

Multiple Myeloma: Big Survival Gains from Novel Agents 'in the Real World'

41

From the European Hematology Association 2010 Congress: For Patients with Follicular Lymphoma, Rituximab Maintenance Therapy Cuts Risk of Recurrence in Half (Phase III PRIMA Study)

42

What I Love About Hematology/Oncology: Muzaffar H. Qazilbash, MD

43

What I Love About Hematology/Oncology: Margaret Kasner, MD, MSCE

44

What I Love About Hematology/Oncology: Pamela Crilley, DO

45

How Health IT is Changing Oncology

46

Are You Providing Adequate Palliative Care?

47

CMS Innovation

48

Chemotherapy Order Sets—Lessons Learned

49

Are You Giving Patients What They Want?

50

A Clinical Research Consortium for MDS

51

Colleague Conversations: Palliative Care in Oncology

52

Research Spotlight: MET Amplification as Driver for NSCLC

53

OncTimes Talk Research Review May 2021

54

Straight Talk with Dr. Brian J. Bolwell: Values

55

Straight Talk with Dr. Brian J. Bolwell: Moments

56

Young Investigators: Liam Holt, PhD, Examines High Compression on Cells & Cancer

57

Straight Talk with Dr. Brian Bolwell: Letting it Go

58

Talking About Leadership With Brian J. Bolwell, MD, FACP

59

A Closer Look at Ultra-Rare Cancers

60

Roswell Park’s Candace S. Johnson & Congressman Brian Higgins on the Promise of Biden’s Cancer Moonshot

61

ASH 2021 Revisited: Plenary Sessions, ZUMA-7 & COVID Vaccines

62

OncTimes Talk Research Review February 2022: Dr. Stephen Hahn, COVID, 2021 World Cancer Leaders’ Summit & Cervical Cancer News

63

ASH 2021 Recap: COVID-19 in Patients with Acute Leukemias & Myelodysplasia In Conversation with Dr. Pinkal Desai

64

ASH 2021 Recap: Multi Omics Sheds New Light on Malignant Transformation from Myeloproliferative Neoplasm to AML

65

Study Recap: After 6 Months, Pfizer COVID Vaccine Remains Effective Against Hospitalizations

66

ASCO 2022 Small Bytes Episode 2: Dr. Julia C. Tchou on Telehealth Weight Loss Program for Breast Cancer Survivors

67

ASCO 2022 Small Bytes: Dr. Alexander I. Spira on KRYSTAL-1 for Patients with Advanced/Metastatic NSCLC

68

Colleague Conversations: A Look at Germline Predisposition to Hematologic Malignancies

69

Refugees & Cancer Care: Ukraine, Lebanon & Beyond Featuring Dr. Richard Sullivan & Dr. Deborah Mukherji

70

Unpacking the Role of Emotions in Mastectomy Decisions with Clara N. Lee, MD

71

Mitigating the Effects of Climate Change on Cancer Care With Robert A. Hiatt, MD, PhD

72

Anil K. Rustgi, MD, on the Current State of Colorectal Cancer Screening

73

Small Bytes: How ctDNA Liquid Biopsies Can Detect Myeloid Malignancies & Occult Tumors

74

Small Bytes: Phase I Study Finds Pan-AKT Inhibitor Ipatasertib Safe & Effective, Featuring Carolyn McCourt, MD

75

Dr. Lisa Newman on Eliminating Racial Disparities in Breast Cancer

76

HemOnc Highlights: Dr. Naveen Pemmaraju on the Benefits of Tagraxofusp for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

77

5 Questions on Making Cardio-Oncology More Accessible to Diverse Patient Populations with Dr. Sandeep Mittan

78

ESMO 2022: For Desmoid Tumor, First Proven Therapy Shows Clear Benefit, “Should Become Standard”

79

ESMO 2022: PATHFINDER Presents Screening Paradigm Shift with A Blood Test to Facilitate Early Detection

80

OncTimes Talk Research Review August 2022: Focus on Breast Cancer

81

Metastatic Hormone-Sensitive Prostate Cancer: Extending Life By Adding a Third Drug to Standard Regimens with Dr. Vincent Khoo

82

Liquid Biopsy ctDNA Prediction of Lung Cancer Relapse “Ready for Prime Time”

83

ASCO 2022 Small Bytes Episode 3: Dr. Marla Lipsyc-Sharf on Personalized ctDNA Testing in Late, HR+, HER2-Negative Breast Cancer

84

Meet the New Oncology Times Editorial Board Chair: Stephanie L. Graff, MD, FACP

85

Ravi B. Parikh, MD, on How Machine Learning-Triggered Reminders Can Improve End-of-Life Care for Cancer Patients

86

Deanna Gerber, MD, on Navigating Cervical Cancer Screening

87

January Research Review: Promising Results in HemOnc Clinical Trials

88

Unraveling a Complex Disease: Gary K. Schwartz, MD, on Sarcoma Research Highlights, Targeted Agents & Future Directions

89

ASH 2022: David Sallman, MD, Discusses Positive Phase I Dose Escalation Data for PRGN-3006 UltraCAR-T in AML Patients

90

Emerging Cancer Treatments for Esophageal Cancer with Brian Henick, MD

91

Full Compliance With Adjuvant Endocrine Therapy Brings 15 Percent Superior Survival in Patients With Breast Cancer

92

Being Obese & Overweight Reduces Efficacy of Extended Endocrine Therapy in HR+ Breast Cancer

93

ASCO 2023: Neoadjuvant Pembrolizumab Brought Big Benefit in Early-Stage Non-Small Cell Lung Cancer with Heather A. Wakelee, MD, FASCO

94

ASCO 2023: How AI Can Help Physicians Communicate with Dying Patients Better & Also Reduce Costs

95

Targeted Adjuvant Therapy in Non-Small Cell Lung Cancer with Roy Herbst, MD PhD

96

Targeted Adjuvant Therapy in Non-Small Cell Lung Cancer with Roy Herbst, MD PhD

97

Adjuvant ATR Inhibition Prolonged Life in Patients with Relapsed Small Cell Lung Cancer

98

Mitophagy Discovered as Potential Reason for AML’s Resistance to Venetoclax

99

Unintentional Bias of Breast Cancer Randomized Clinical Trial Interpretations Through Discontinuation Imbalance

100

Trastuzumab Deruxtecan Benefits Patients with HER2-Low Metastatic Breast Cancer Irrespective of ER Expression

101

Artificial Intelligence Model Predicts Overall Survival in Patients with Metastatic Breast Cancer

102

Axillary Dissection in Older Women With Clinically Node-Negative Breast Cancer

103

Variability of Biological Parameters Between Tumor Biopsy & Surgical Samples in Breast Cancer Patients

104

Sabestomig in Non-Small Cell Lung Cancer: Bi-Specific Antibody Safe and Active

105

Radicals Study Finds Adjuvant Radiotherapy No Benefit After Radical Prostatectomy

106

Double TKI Therapy Improves Responses in MET Amplification-Driven EGFR-Mutant Non-Small Cell Lung Cancer

107

Two Drug Combination Benefits Patients with nRAS-Mutated Melanoma Refractory to Checkpoint Inhibition

108

CLIC Protein Inhibition Key to Metformin’s Anti-Neoplastic Properties

109

Collagen-Bound Interleukin 12 Converts “Cold” Tumors into “Hot” Ones

110

INTERLACE Study Boosts Cervical Cancer Survival

111

Afatinib Recommended for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations

112

RET Fusion-Targeted Drug Doubles Progression-Free Survival in NSCLC Patients

113

Adjuvant Radiotherapy No Benefit After Radical Prostatectomy

114

Collagen-Bound Interleukin 12 Converts “Cold” Tumors Into “Hot” Ones

115

Allogeneic Transplant for AML: Only in Patients Negative for Molecular Minimum Residual Disease

116

Antibody-Drug Conjugate Brings Success in High-Risk R/R Follicular Lymphoma

117

Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL

118

Relapsed or Refractory CLL - With Sameer A. Parikh, MBBS, and Alessandra Ferrajoli, MD

119

CLL Frontline Treatment - With Sameer A. Parikh, MBBS, & Alessandra Ferrajoli, MD

120

Gene Test Shows Which Triple-Negative Breast Cancers Do Not Need Pre-Op Pembrolizumab

121

Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia

122

Important Mantle Cell Lymphoma Findings From the Sympatico Study

123

World’s Largest Prostate Cancer Trial, STAMPEDE, Celebrates 20 Years of Progress

124

Doublet Inhibitor Therapy Restrains Metastatic EGFR-Mutated NSCLC Progression

125

Gene-Targeted Agent Brings Clinical Benefit in R/R Acute Leukemias

126

Trastuzumab Deruxtecan Delays Progression in HR+, HER2-low, and HER2 Ultralow Breast Cancer After Endocrine Therapy

127

German Study Finds New Regimen for Hodgkin Lymphoma More Effective, Less Toxic

128

Study Finds Durvalumab Improved Progression-Free and Overall Survival in Limited Stage Small Cell Lung Cancer

129

Study Supports Osimertinib as Standard of Care for Patients With Locally Advanced EGFR-Mutated NSCLC

130

Earliest Detection of Cancer by Artificial Intelligence Analysis of Circulating Cell-Free DNA Fragmentomes

131

Kinase Inhibitor Delivers Synthetic Lethality to Enhance Radiotherapy in Glioblastoma

132

mRNA Vaccine + Checkpoint Inhibitor Combo Had Low Toxicity With Evidence of Efficacy in Advanced NSCLC

133

Bispecific Dual Checkpoint Blockade Extends Life & Slows Progression in Gastric & GE Junction Cancers

134

Exercise Deters Prostate Cancer Death & Progression

135

Bispecific T-cell Engager Antibody Brings Deep, Durable Remissions in R/R Multiple Myeloma

136

Exosome-Based Liquid Biopsy Promises Very Early Pancreatic Cancer Detection

137

Polyepitopic Personalized Vaccine Brought Durable Immune Responses & Clinical Benefit in Resected Head & Neck Cancers

138

Mesh-Supported Prepectoral Method of Breast Reconstruction After Breast Cancer Surgery

139

Radiotherapy Boost Protects Young Patients With Early Breast Cancer, High Dose Boost Not Needed

140

Breast-Conserving Therapy Effective for Ductal Carcinoma in Situ, But Questions Remain

141

Three-Node Breast Cancer Spread: Most Patients Can Safely Avoid Axillary Dissection

142

Artificial Intelligence Tool Predicts Postoperative Radiotherapy Lymphedema

143

Neoadjuvant Pembrolizumab Improves High-Risk Early Breast Cancer Outcomes

144

Preoperative Partial Breast Irradiation: Marked Benefit in Low-Risk Breast Cancer

145

Adjuvant Atezolizumab: No Survival Benefit in Triple-Negative Breast Cancer

146

ESMO Reports Neoadjuvant Therapy for TNBC, Combination Checkpoint Inhibition, Artificial Intelligence & More

147

Emerging Potential for Cell Therapies in Ovarian Cancer and Other Solid Tumors

148

Global Cooperation on Antibody-Drug Conjugates: Key Driver of Progress in HER2-Dependent Metastatic Breast Cancer Treatment

149

Breastfeeding is Safe After Treatment for BRCA-Positive Breast Cancer

150

World-Wide Clinical Perspectives from Chinese Society of Clinical Oncology’s Globally Upscale 2024 Annual Meeting

151

Breastfeeding After Hormone Receptor-Positive Breast Cancer: No Detectable Risk for Patients

152

Findings at ESMO 2024 Highlighting the Benefit of Neoadjuvant Therapies

153

A Multi-Drug Algorithm Used to Accurately Predict Best First-Line Treatments in Patients With Newly Diagnosed Acute Myeloid Leukemia

154

Immune-Related Adverse Events Predict Response to Checkpoint Inhibitor Monotherapy in Advanced Head & Neck Cancers

155

Proton Pump Inhibitors Bigger Impact on Dasatinib Efficacy in CML Than Previously Thought

156

Lymphadenectomy Can Be Safely Omitted for Patients With Advanced Epithelial Ovarian Cancer Lacking Suspicious Lymph Nodes

157

MUC-1 Vaccine Delays Breast Cancer Distant Recurrence & Extends Survival

158

Neoadjuvant Checkpoint Inhibitor Combination Beats Standard Surgery With Adjuvant Immunotherapy in Macroscopic, Resectable Stage III Melanoma

159

Telehealth Triumphs for Palliative Care Delivery in Patients With Lung Cancer

160

Asciminib May Be a Safer, More Effective Treatment for Patients With Newly Diagnosed Chronic Myeloid Leukemia

161

Chemotherapy Before and After Surgery Improved Outcomes for Patients With Resectable Locally Advanced Esophageal Adenocarcinoma

162

Breastfeeding is Safe After Treatment for BRCA-Positive Breast Cancer

163

Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified

164

Early Switch to Immunotherapy Recommended After BRAFV600 Mutation Targeted Therapy for Advanced Melanoma

165

Tumor-Agnostic Classifier & Screener Aids Targeted Drug Development

166

Clear Benefit From Early Checkpoint Inhibition in Locally Advanced, High-Risk Cervical Cancer

167

Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified

168

The New Standard: Testing for All Therapy-Matched DNA and RNA Biomarkers Up Front

169

Digital Twin Brings AI Power to Individualize Cancer Management

170

Wnt Signaling Pathway Inhibitor Suggests Toxicity-Free Cure Potential for Hepatoblastoma

171

Anti-HER2 Combination Found Effective in HER2-Altered Bile Duct Cancers

172

FGFR-3 Inhibitor Has Early Clinical Activity in Advanced Urothelial Cancer

173

Antibody-Drug Conjugate “Promising Efficacy” in HER2-Positive and HER2-Low Breast Cancer

174

Radiation Delivery by Mini Protein Brings Promise for Metastatic Urothelial & Other Solid Tumors

175

Advanced Melanoma: CheckMate 067 10-Year Data Show Prognoses Transformed By Checkpoint Inhibitors

176

Perioperative Checkpoint Inhibition Better for Muscle-Invasive Bladder Cancer

177

Preoperative Chemoradiation Ruled Out for Gastric or GE Junction Resectable Adenocarcinoma

178

Recurrent Glioma: Encouraging Responses to Autologous Myeloid Dendritic Cell Therapy

179

Resectable Stage III Melanoma: Unprecedented Survival Benefit With Pure Checkpoint Inhibitor Neoadjuvant Therapy

180

Therapeutic mRNA Vaccine Brings New Hope in Glioblastoma

181

Circulating Tumor DNA Directs Precision Management for Ovarian Cancer

182

Cardio-Oncology: Many Cancer Treatment Cardiotoxicities Still to Be Understood

183

From Ironman to Advocate: Tom Hulsey’s Journey Through Prostate Cancer and Purpose

184

Accurate and Actionable: How Oncologists Get Fast, Comprehensive Therapeutic Insights from the OncoExTra® Test

185

Empowering Cancer Care Through Movement: A Conversation with Sami Mansfield

186

Defying the Odds: Katie Coleman's Journey from Diagnosis to Advocacy

187

Making Comprehensive Genomic Profiling More Accurate for Everyone: The Importance of Patient-Matched Tumor-Normal Sequencing

188

Transforming colorectal cancer management with tumor informed ctDNA testing

189

Lessons in Resilience: Dr. Susan MacDonald's Healthcare Journey

190

Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities at High Risk

191

Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer

192

Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities

193

Novel Score Selects Patients With Intermediate Risk Prostate Cancer Safe for Active Surveillance

194

Striking Microbiome Bacterial Population Differences Distinguish Metastatic Prostate Cancer From Non-Metastatic Disease

195

Episode 1, A Precision Medicine Approach for Advanced Ovarian Cancer

196

Episode 2, HRD Testing Deep-Dive

197

Episode 3, Better Informed Patient Journeys

198

KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma